Table 2 Significant factors in multivariate analysis
Hazard ratio | 95% confidence interval | P-value | |
|---|---|---|---|
Biochemical recurrence free survival | |||
T stage ≤2a | 1.7 | 1.1-2.5 | 0.014 |
PSA <10ng/ml | 1.9 | 1.2-2.8 | 0.003 |
no PSA progression vs. PSA pr. with HT | 3.4 | 1.9-6.0 | <0.001 |
no PSA progression vs. no HT | 1.5 | 1.2-21 | 0.024 |
nadir ≤0.5 vs. >0.5 after initial HT | 4.7 | 1.1-19 | 0.034 |
Disease specific survival | |||
Gleason score ≤6 | 4.0 | 1.8-9.1 | 0.001 |
no HT vs. PSA progression with HT | 23 | 7.3-72 | <0.001 |
no PSA progression vs. PSA pr. with HT | 9.1 | 3.7-22 | <0.001 |
Overall survival | |||
age <70years | 2.6 | 1.5-4.4 | <0.001 |
Gleason score ≤6 | 2.2 | 1.4-3.7 | 0.002 |
no HT vs. PSA progression with HT | 5.2 | 3.6-9.4 | <0.001 |
no PSA progression vs. PSA pr. with HT | 7.2 | 3.9-14 | <0.001 |